WILLOW ANNOUNCES INITIATION OF STRATEGIC REVIEW PROCESS
Willow Biosciences (TSX: WLLW, OTCQB: CANSF), a biotechnology company focused on sustainable ingredient manufacturing, has announced the initiation of a formal strategic review process. The decision comes after unsuccessful attempts to secure financing under favorable shareholder terms amid challenging capital market conditions.
The strategic alternatives under consideration include:
- Sale of all or part of Willow's business and assets
- Complete company sale
- Merger with a third party
- Joint ventures
- Royalty or licensing arrangements
- Introduction of new strategic shareholders
- Various financing alternatives
The company has established a virtual data room for interested parties to review information upon signing a confidentiality agreement. While no definitive timeline has been set, management believes this process will benefit shareholders. The company does not plan to provide regular updates unless necessary or until a definitive transaction is approved.
Willow Biosciences (TSX: WLLW, OTCQB: CANSF), un'azienda biotecnologica focalizzata sulla produzione di ingredienti sostenibili, ha annunciato l'avvio di un processo formale di revisione strategica. La decisione è stata presa dopo tentativi non riusciti di ottenere finanziamenti a condizioni vantaggiose per gli azionisti in un contesto di mercato dei capitali sfavorevole.
Le alternative strategiche in esame includono:
- Vendita totale o parziale dell'azienda e dei beni di Willow
- Vendita completa della società
- Fusione con una terza parte
- Joint venture
- Accordi di royalty o licenza
- Introduzione di nuovi azionisti strategici
- Varie alternative di finanziamento
L'azienda ha istituito un data room virtuale per le parti interessate, affinché possano esaminare le informazioni previa sottoscrizione di un accordo di riservatezza. Sebbene non sia stato fissato un cronoprogramma definitivo, la direzione crede che questo processo porterà benefici agli azionisti. La società non prevede di fornire aggiornamenti regolari a meno che non sia necessario o fino all'approvazione di una transazione definitiva.
Willow Biosciences (TSX: WLLW, OTCQB: CANSF), una empresa biotecnológica centrada en la fabricación de ingredientes sostenibles, ha anunciado el inicio de un proceso formal de revisión estratégica. La decisión se produce después de intentos fallidos de asegurar financiamiento bajo condiciones favorables para los accionistas en un contexto de mercado de capitales complicado.
Las alternativas estratégicas en consideración incluyen:
- Venta total o parcial del negocio y activos de Willow
- Venta completa de la empresa
- Fusión con una tercera parte
- Joint ventures
- Acuerdos de regalías o licencias
- Introducción de nuevos accionistas estratégicos
- Varias alternativas de financiamiento
La empresa ha establecido una sala de datos virtual para que las partes interesadas revisen la información tras la firma de un acuerdo de confidencialidad. Aunque no se ha fijado un cronograma definitivo, la dirección cree que este proceso beneficiará a los accionistas. La empresa no planea proporcionar actualizaciones regulares a menos que sea necesario o hasta que se apruebe una transacción definitiva.
Willow Biosciences (TSX: WLLW, OTCQB: CANSF), 지속 가능한 원료 제조에 중점을 둔 생명공학 회사는 공식적인 전략 검토 프로세스의 시작을 발표했습니다. 이 결정은 불리한 자본 시장 상황 속에서 주주에게 유리한 조건으로 재정 지원을 확보하기 위한 시도가 실패한 이후에 내려졌습니다.
검토 중인 전략적 대안은 다음과 같습니다:
- Willow의 사업 및 자산 전부 또는 일부 판매
- 회사의 완전한 매각
- 제3자와의 합병
- 조인트 벤처
- 로열티 또는 라이센스 계약
- 새로운 전략적 주주 도입
- 다양한 재정 지원 대안
회사는 관심 있는 당사자들이 비밀 유지 계약에 서명한 후 정보를 검토할 수 있도록 가상 데이터룸을 마련했습니다. 확정된 일정은 없지만, 경영진은 이 과정이 주주에게 이롭다고 믿고 있습니다. 회사는 필요하지 않는 한 정기적인 업데이트를 제공할 계획이 없습니다.
Willow Biosciences (TSX: WLLW, OTCQB: CANSF), une entreprise de biotechnologie axée sur la fabrication d'ingrédients durables, a annoncé le lancement d'un processus formel de révision stratégique. Cette décision intervient après des tentatives infructueuses d'obtenir un financement à des conditions favorables aux actionnaires dans un contexte de marché des capitaux difficile.
Les alternatives stratégiques envisagées incluent :
- Vente de la totalité ou d'une partie des activités et des actifs de Willow
- Vente complète de l'entreprise
- Fusion avec une tierce partie
- Partenariats
- Accords de redevances ou de licences
- Introduction de nouveaux actionnaires stratégiques
- Différentes options de financement
L'entreprise a mis en place une salle de données virtuelle pour que les parties intéressées puissent examiner les informations après la signature d'un accord de confidentialité. Bien qu'aucun calendrier définitif n'ait été fixé, la direction estime que ce processus sera bénéfique pour les actionnaires. L'entreprise ne prévoit pas de fournir des mises à jour régulières, sauf si cela s'avère nécessaire ou jusqu'à ce qu'une transaction définitive soit approuvée.
Willow Biosciences (TSX: WLLW, OTCQB: CANSF), ein Biotechnologieunternehmen, das sich auf die Herstellung nachhaltiger Inhaltsstoffe konzentriert, hat den Start eines formalen strategischen Überprüfungsprozesses bekannt gegeben. Die Entscheidung fiel nach gescheiterten Versuchen, Finanzierungen unter günstigen Bedingungen für die Aktionäre in einem schwierigen Kapitalmarktumfeld zu sichern.
Die in Betracht gezogenen strategischen Alternativen umfassen:
- Verkauf aller oder eines Teils von Willows Geschäft und Vermögenswerten
- Vollständiger Unternehmensverkauf
- Fusion mit einem Dritten
- Joint Ventures
- Lizenz- oder Lizenzvereinbarungen
- Einführung neuer strategischer Aktionäre
- Verschiedene Finanzierungsalternativen
Das Unternehmen hat einen virtuellen Datenraum eingerichtet, damit interessierte Parteien Informationen nach Unterzeichnung einer Vertraulichkeitsvereinbarung überprüfen können. Obwohl kein definitiver Zeitplan festgelegt wurde, ist die Unternehmensleitung der Ansicht, dass dieser Prozess den Aktionären zugutekommen wird. Das Unternehmen plant nicht, regelmäßige Updates bereitzustellen, es sei denn, es ist notwendig oder bis eine endgültige Transaktion genehmigt wird.
- Creation of virtual data room for potential buyers/partners indicates active pursuit of alternatives
- Multiple strategic options being considered to maximize shareholder value
- Unable to secure financing on favorable terms
- Challenging capital market conditions affecting company operations
- No guarantee of successful transaction outcome
- Possible asset sale indicates financial distress
Willow's board of directors has determined it is timely, prudent and in the best interests of the Company and its stakeholders to commence a formal process to explore strategic alternatives. To date, the Company has been unsuccessful in procuring any form of financing on terms that are in the best interest of shareholders. Given the challenging capital market conditions, the Company has initiated a review of available strategic alternatives with a view to maximizing and accelerating the value of Willow's assets. Strategic alternatives may include, but are not limited to, a sale of all or a material portion of Willow's business and assets, either in one transaction or in a series of transactions, the outright sale of Willow, a merger or other transaction involving Willow and a third party, joint ventures, royalty or licensing arrangements, introduction of a new significant strategic shareholder, various financing alternatives or other significant transaction.
There are no assurances that a transaction will be undertaken as a result of this strategic review process. It is Willow's current intention not to disclose developments with respect to the process, periodically or otherwise, unless and until the board of directors has approved a definitive transaction or strategic alternative or otherwise determines that disclosure is necessary or appropriate. Willow cautions that there are no assurances or guarantees that the process will result in a transaction or, if a transaction is undertaken, the terms or timing of such a transaction. Willow has not yet set a definitive schedule to complete its identification, examination and consideration of strategic alternatives. The board and management team of Willow believe that this strategic review process will ultimately benefit shareholders.
Willow has created a virtual data room, which is available for review by interested parties upon execution of a confidentiality agreement.
About Willow Biosciences Inc.
Willow develops biomanufacturing processes for producing high value ingredients in pharmaceutical, food and beverage, agriculture, and consumer markets. Willow's FutureGrown™ and BioOxi™ platforms enable large-scale production with sustainability at its core. Willow's R&D team has a proven track record of developing and commercializing bio-based manufacturing processes and products to benefit our B2B partners and their customers. For more information, visit www.willowbio.com.
FutureGrown™ and BioOxi™ are registered trademarks of Willow Biosciences Inc.
Forward-Looking Statements
This news release may include forward-looking statements including opinions, assumptions, estimates and the Company's assessment of future plans, platforms and operations, and, more particularly, without limitation, statements concerning the strategic process and any transaction or transactions resulting from the strategic process, including the expectation that the strategic process may elicit change and enhance shareholder value. When used in this news release, the words "will," "anticipate," "believe," "estimate," "expect," "intent," "may," "project," "should," and similar expressions are intended to be among the statements that identify forward-looking statements. The forward-looking statements are founded on the basis of expectations and assumptions made by the Company which include, but are not limited to: the success of the strategic process; the availability of alternative financing sources to the Company; the success of Willow's strategic partnerships and the development of future strategic partnerships; the success of Willow's development programs and anticipated demand and benefits thereof; the financial strength of the Company; the ability of the Company to fund its business plan using cash on hand and existing resources; the market for Willow's products; the ability of the Company to obtain and retain applicable licences; the ability of the Company to obtain suitable manufacturing partners and other strategic relationships; and the successful implementation of Willow's commercialization and production strategy, generally. Forward-looking statements are subject to a wide range of risks and uncertainties, and although the Company believes that the expectations represented by such forward-looking statements are reasonable, there can be no assurance that such expectations will be realized. Any number of important factors could cause actual results to differ, including, but not limited to: risks inherent in the biotechnology industry in general; the failure to achieve the anticipated benefits of the strategic process or any transactions undertaken pursuant to the strategic process; the success of the Company's research and development strategies; infringement on intellectual property; failure to benefit from partnerships; the risk that financing alternatives may not be available on favourable terms or at all; actions and initiatives of federal, state and provincial governments and changes to government policies and the execution and impact of these actions, initiatives and policies; competition from other industry participants; adverse
The forward-looking statements contained in this news release are made as of the date hereof and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, except as required by applicable law. The forward-looking statements contained herein are expressly qualified by this cautionary statement.
View original content to download multimedia:https://www.prnewswire.com/news-releases/willow-announces-initiation-of-strategic-review-process-302354869.html
SOURCE Willow Biosciences Inc.
FAQ
What strategic alternatives is Willow Biosciences (CANSF) considering in its 2025 review?
Why did Willow Biosciences (CANSF) initiate a strategic review in January 2025?
How can interested parties access Willow Biosciences' (CANSF) data room?
Will Willow Biosciences (CANSF) provide regular updates about the strategic review process?
